Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: J. Uriach and Company
• Treatments: Insulin; Insulin, Globin Zinc; Salicylates; Triflusal

Criteria

Inclusion Criteria:

• Ages 35 to 60 years old